AstraZeneca's CEO sees 19% pay cut

What does it take to cut a CEO's compensation package by almost 20 percent? Ask David Brennan (photo), head honcho at AstraZeneca. Brennan made 2.15 million pounds ($4.3 million) in 2007, about $2 million of that as base salary and the rest variable compensation. Though his base was set at 5.5 percent higher in 2007 than 2006, his total package dropped by 19 percent because of smaller bonus and decreased reimbursements for relocation expenses. (Brennan moved to the U.K. from the U.S. in January 2006, when he took over as CEO).

Still, Brennan's package didn't drop as much as AstraZeneca's stock did. Shares fell by 21 percent last year. And apparently Brennan is willing to take the hit. According to the blog PharmaGossip, he turned down "an almost double-digit" pay increase for 2008.

- read AstraZeneca's compensation chart for 2007 (pp. 106-107)
- check out the 2006 details (p. 88)
- see Pharma Gossip's item

Related Articles:
Analyst: AZ "worst performer" in pharma. Report
AstraZeneca--Top 8 layoffs of 2007. Report
AstraZeneca lays out road map for recovery. Report 

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.